Le Lézard
Classified in: Health
Subjects: SVY, FDA

New FDA-Approved Nasal Spray Anti-Depressant SPRAVATOtm Now Available in Bay Area at Palo Alto Mind Body


PALO ALTO, Calif., March 14, 2019 /PRNewswire/ --  By age 22, Victor C. had tried everything in his battled against severe depression and was losing hope. Last year he found new hope with intravenous ketamine infusions.  Ketamine lifted his depression. "I felt reborn," he said. "There is no other way to put it. It's indescribable." With the FDA approval of SPRAVATOtm (www.paloaltomindbody.com/services/spravato) ketamine-based nasal spray, others like Victor have new hope in their battle against severe depression.

Victor first benefited from intravenous ketamine infusions administered at Palo Alto Mind Body under the direction of Dr. M Rameen Ghorieshi (www.paloaltomindbody.com/provider/m-rameen-ghorieshi-md-mph).  After initial treatments, Victor transitioned to a maintenance routine involving an off-label ketamine nasal spray. This enabled him to maintain progress made with ketamine infusions and reduce the frequency of booster infusions. FDA's approval of SPRAVATOtm affirms what Victor knows: ketamine-based treatments work.  Furthermore, FDA approval clears the path for patients like Victor to receive support from insurance.

Dr. Ghorieshi, one of the first certified providers of SPRAVATOtm in the Bay Area, is now seeing new patients interested in SPRAVATOtm.   "We've successfully administered over 1000 ketamine treatments to patients with severe depression, anxiety, PTSD, and chronic pain.  The results are tremendously positive," said Dr. Ghorieshi. "This is an amazing opportunity to help a broader range of patients. FDA approval, often followed by insurance coverage, is important to many patients. Additionally, the nasal spray is a great alternative for those uneasy about receiving infusions." 

After more than 1000 IV ketamine treatments (www.paloaltomindbody.com/services/iv-ketamine-infusions), Dr. Ghorieshi reports that 87% of patients have experienced significant improvement and 35% of those consider the improvement to be "life-changing."

In August 2018, Victor hoped to return to college. With ketamine, he took control of his life, returned to school, and finished with a 3.9 average.  "I know many people struggling with depression who don't know what to do. I now have confidence that there's a future," he said.

Palo Alto Mind Body with Janssen CarePath helps patients understand affordable options to seek treatment with SPRAVATOtm including insurance verification and discounts.

Palo Alto Mind Body
550 Hamilton Avenue, Ste. 215
Palo Alto, CA 94301
650-685-2900
www.paloaltomindbody.com

 

SOURCE Palo Alto Mind Body


These press releases may also interest you

at 22:03
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...



News published on and distributed by: